Skip to main content

Canadian at work on COVID-19 vaccine is optimistic

#290 of 1611 articles from the Special Report: Coronavirus in Canada
Chil-Yong Kang, PhD, professor emeritus, Department of Microbiology and Immunology and his team developed the first and only preventative HIV vaccine and now he's working on a vaccine for COVID-19.
Picture of Chil-Yong Kang, PhD, professor emeritus, Department of Microbiology and Immunology at University of Western Ontario Schulich School of Medicine and Dentistry. Photo courtesy Western University

Support strong Canadian climate journalism for 2025

Help us raise $150,000 by December 31. Can we count on your support?
Goal: $150k
$40k

"We know our vaccine is safe. Therefore, I will stick out my arm as the first vaccinee," said Chil-Yong Kang, PhD, DSc, FRSC, Professor of Virology in the Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry at the University of Western Ontario.

Kang is a Canadian scientist who developed a preventative HIV vaccine which is currently in human clinical trials. Now, his research team is working round-the-clock on a vaccine for SARS-CoV-2, the virus that causes COVID-19.

Kang says his team is using its "well-established VSV (Vesicular Stomatitis Virus)-based platform technology" to create an effective vaccine against COVID-19. The same platform technology has been used successfully in his laboratory for the development of a vaccine for MERS (Middle East Respiratory Syndrome), another coronavirus disease. He says he is optimistic about having a preventive SARS-CoV-2 vaccine ready for testing soon.

His team is working 12-hour days, coming into the laboratory seven days a week to make their COVID-19 vaccine testable within three months, he says. That's breakneck speed for developing a vaccine for a new virus, which normally take years to develop, given that traditional vaccines take between eight and 10 years to develop. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases (NIAID), estimated that a vaccine could be ready for the general public in around 18 months.

The media resource for URL https://www.youtube.com/watch?v=QaowxYgJeHY?wmode=opaque&controls=&rel=0&showinfo=0 could not be retrieved.
Zoom interview by Linda Solomon Wood with Chil-Yong Kang, edited for brevity

But because of the urgency to halt the COVID-19 pandemic, Kang says he'd like to see the Canadian government fast-track vaccines for human clinical trial. And that’s one of the reasons Kang and his team are working around the clock.

"Vaccines have to be safe. No matter how effective the vaccine is, if it isn't safe, we cannot use it," he says. "It [also] has to be effective. Ideally, we want to have a vaccine which can prevent over 90 per cent of infection."

The Government of Canada has provided funding for the research, nearly a million dollars through Canadian Institutes of Health Research.

Other Canadian universities working to find a vaccine are at McMaster University, University of Alberta, Laval University, University of British Columbia, University of Saskatchewan and University of Manitoba.

Kang says in the near future he's going to need much more support for the human clinical trials.

Comments